From Dr. Fabio’s blog post:
Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available? How do they compare? What are the parameters for successful imaging?
We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review. We hope you find this review useful.
Read the entire article on drfabio.com HERE
Opinion Article by Charles Maack
The information in this article is a lengthy read, but for men moved to androgen deprivation therapy the information is extremely important to be aware since everything explained may be involved in their well-being.
Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of:
- a LHRH/GnRH agonist or antagonist to shut down testicular testosterone production
- an antiandrogen to block testosterone access to the cancer cell nucleus
- a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT
Read the entire article on oncogen.org HERE
As many as 40% of newly diagnosed PCa patients have unifocal disease, that is, just one focus of cancer. But that still leaves 60-80% of patients with multifocal PCa. Without evidence to the contrary, multiple foci in the same gland were thought to be biologically homogeneous, that is, identical to each other.
Then, along came the tools to analyze PCa at the molecular level, bringing new knowledge of the biology of PCa.
Read about this by clicking here.
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Learn more about these interesting findings by clicking HERE.
Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.
When this happens, the question that comes is what should be the next treatment? Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).
Knowing which of these two options is best has been nothing but guesswork. But, things are improving. There is an investigational test that detects the expression of a protein called AR-V7 in the nuclei of circulating tumor cells taken from a vial of blood cells (liquid biopsy). This test can help guide this decision.
A recent study (published in JAMA Oncology) evaluating this test has shown that a blood test can detect the protein called AR-V7 in circulating tumor cells and that the presence of this protein accurately predicts how well certain men will respond to AR inhibitors (Zytiga and Xtandi).
Read the complete blog on CancerABCs.org HERE
The U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men.
Read more on PCF.org HERE
It has just been recently announced that the U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa. It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Read the complete article on CancerABCs.org HERE
An exciting proof-of-concept study of Lutetium-177 PSMA (Lu PSMA) was published in the journal Lancet Oncology. Lu-PSMA has been described as “a disruptive therapy and has the potential to change practice” in the future treatment of men with end-stage prostate cancer.
Lu-PSMA, a nuclear therapy, has been used in Germany for many years under compassionate use basis. This particular study was conducted in Australia. The study results offer hope for men with end-stage prostate cancer who have exhausted all their treatment options.
Read more on Prostate Cancer Foundation HERE
and CancerABCs.org HERE
and SBS News HERE
UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer. Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments in mice and with human cells showed that blocking this stress response with an experimental drug—previously shown to enhance cognition and restore memory after brain damage in rodents—causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.
The new study was published online May 2, 2018 in Science Translational Medicine.
Read the entire article on MedicalXpress.com HERE
and technologyneworks.com HERE
Since 2010, many new agents have joined our armamentarium for treating metastatic CRPC, raising the question of how best to sequence them. For men with newly diagnosed, presumably hormone-sensitive mPC, we usually start treatment with either abiraterone acetate or docetaxel. Therefore, although we have five or six approved treatments for mCRPC, not every patient should receive all of them.
Click here to read more…….